FOLD Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals has a net margin of -17.31% compared to Amicus Therapeutics's net margin of -9.67%. Amicus Therapeutics's return on equity of -17.7% beat Alnylam Pharmaceuticals's return on equity of --.

Amicus Therapeutics has a consensus price target of $15.82, signalling upside risk potential of 162.33%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $320.62 which suggests that it could grow by 5.47%. Given that Amicus Therapeutics has higher upside potential than Alnylam Pharmaceuticals, analysts believe Amicus Therapeutics is more attractive than Alnylam Pharmaceuticals.

Amicus Therapeutics has a beta of 0.538, which suggesting that the stock is 46.155% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.218, suggesting its less volatile than the S&P 500 by 78.213%.

Amicus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

Amicus Therapeutics quarterly revenues are $125.2M, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $594.2M. Amicus Therapeutics's net income of -$21.7M is higher than Alnylam Pharmaceuticals's net income of -$57.5M. Notably, Amicus Therapeutics's price-to-earnings ratio is -- while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics is 3.39x versus 16.64x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Blueprint Medicines has a net margin of -17.31% compared to Amicus Therapeutics's net margin of 0.33%. Amicus Therapeutics's return on equity of -17.7% beat Blueprint Medicines's return on equity of -49.13%.

Amicus Therapeutics has a consensus price target of $15.82, signalling upside risk potential of 162.33%. On the other hand Blueprint Medicines has an analysts' consensus of $126.87 which suggests that it could fall by -0.86%. Given that Amicus Therapeutics has higher upside potential than Blueprint Medicines, analysts believe Amicus Therapeutics is more attractive than Blueprint Medicines.

Amicus Therapeutics has a beta of 0.538, which suggesting that the stock is 46.155% less volatile than S&P 500. In comparison Blueprint Medicines has a beta of 0.841, suggesting its less volatile than the S&P 500 by 15.895%.

Amicus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Blueprint Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics pays -- of its earnings as a dividend. Blueprint Medicines pays out -- of its earnings as a dividend.

Amicus Therapeutics quarterly revenues are $125.2M, which are smaller than Blueprint Medicines quarterly revenues of $149.4M. Amicus Therapeutics's net income of -$21.7M is lower than Blueprint Medicines's net income of $496K. Notably, Amicus Therapeutics's price-to-earnings ratio is -- while Blueprint Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics is 3.39x versus 14.59x for Blueprint Medicines. Usually stocks with elevated PS ratios are considered overvalued.

Ultragenyx Pharmaceutical has a net margin of -17.31% compared to Amicus Therapeutics's net margin of -108.46%. Amicus Therapeutics's return on equity of -17.7% beat Ultragenyx Pharmaceutical's return on equity of -205.06%.

Amicus Therapeutics has a consensus price target of $15.82, signalling upside risk potential of 162.33%. On the other hand Ultragenyx Pharmaceutical has an analysts' consensus of $89.84 which suggests that it could grow by 142.55%. Given that Amicus Therapeutics has higher upside potential than Ultragenyx Pharmaceutical, analysts believe Amicus Therapeutics is more attractive than Ultragenyx Pharmaceutical.

Amicus Therapeutics has a beta of 0.538, which suggesting that the stock is 46.155% less volatile than S&P 500. In comparison Ultragenyx Pharmaceutical has a beta of 0.250, suggesting its less volatile than the S&P 500 by 75%.

Amicus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics pays -- of its earnings as a dividend. Ultragenyx Pharmaceutical pays out -- of its earnings as a dividend.

Amicus Therapeutics quarterly revenues are $125.2M, which are smaller than Ultragenyx Pharmaceutical quarterly revenues of $139.3M. Amicus Therapeutics's net income of -$21.7M is higher than Ultragenyx Pharmaceutical's net income of -$151.1M. Notably, Amicus Therapeutics's price-to-earnings ratio is -- while Ultragenyx Pharmaceutical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics is 3.39x versus 5.86x for Ultragenyx Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -17.31% compared to Amicus Therapeutics's net margin of 23.33%. Amicus Therapeutics's return on equity of -17.7% beat Vertex Pharmaceuticals's return on equity of -6.04%.

Amicus Therapeutics has a consensus price target of $15.82, signalling upside risk potential of 162.33%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.12 which suggests that it could grow by 12.1%. Given that Amicus Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe Amicus Therapeutics is more attractive than Vertex Pharmaceuticals.

Amicus Therapeutics has a beta of 0.538, which suggesting that the stock is 46.155% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.415, suggesting its less volatile than the S&P 500 by 58.544%.

Amicus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Amicus Therapeutics quarterly revenues are $125.2M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Amicus Therapeutics's net income of -$21.7M is lower than Vertex Pharmaceuticals's net income of $646.3M. Notably, Amicus Therapeutics's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics is 3.39x versus 10.41x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.